{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+%28Pbo%29&page=5", "query": { "intervention": "Placebo (Pbo)", "page": 5 }, "page_size": 10 }, "pagination": { "page": 5, "page_size": 10, "total_count": 163, "total_pages": 17, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+%28Pbo%29&page=6&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+%28Pbo%29&page=4&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-02T11:23:18.810Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01763866", "title": "LDL-C Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hyperlipidemia" ], "interventions": [ { "name": "Evolocumab", "type": "BIOLOGICAL" }, { "name": "Ezetimibe", "type": "DRUG" }, { "name": "Placebo to Evolocumab", "type": "DRUG" }, { "name": "Placebo to Ezetimibe", "type": "DRUG" }, { "name": "Atorvastatin", "type": "DRUG" }, { "name": "Rosuvastatin", "type": "DRUG" }, { "name": "Simvastatin", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 2067, "start_date": "2013-01-15", "completion_date": "2013-12-04", "has_results": true, "last_update_posted_date": "2022-11-08", "last_synced_at": "2026-10-02T11:23:18.810Z", "location_count": 65, "location_summary": "Birmingham, Alabama • Glendale, Arizona • Tucson, Arizona + 58 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Carmichael", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01763866" }, { "nct_id": "NCT03895203", "title": "A Study to Test the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Psoriatic Arthritis" ], "interventions": [ { "name": "Bimekizumab", "type": "DRUG" }, { "name": "Adalimumab", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "UCB Biopharma SRL", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 852, "start_date": "2019-04-03", "completion_date": "2022-07-11", "has_results": true, "last_update_posted_date": "2026-09-28", "last_synced_at": "2026-10-02T11:23:18.810Z", "location_count": 25, "location_summary": "Phoenix, Arizona • San Diego, California • Tustin, California + 22 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "San Diego", "state": "California" }, { "city": "Tustin", "state": "California" }, { "city": "Palm Harbor", "state": "Florida" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03895203" }, { "nct_id": "NCT01406938", "title": "Efficacy and Safety of Subcutaneous Secukinumab (AIN457) for Moderate to Severe Chronic Plaque-type Psoriasis Assessing Different Doses and Dose Regimens", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Moderate to Severe Plaque-type Psoriasis" ], "interventions": [ { "name": "AIN457 150mg", "type": "DRUG" }, { "name": "AIN457 300mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 967, "start_date": "2011-08", "completion_date": "2013-05", "has_results": true, "last_update_posted_date": "2015-05-19", "last_synced_at": "2026-10-02T11:23:18.810Z", "location_count": 33, "location_summary": "Fresno, California • Pasadena, California • Sacramento, California + 28 more", "locations": [ { "city": "Fresno", "state": "California" }, { "city": "Pasadena", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01406938" }, { "nct_id": "NCT03896581", "title": "A Study to Evaluate the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Psoriatic Arthritis" ], "interventions": [ { "name": "Bimekizumab", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "UCB Biopharma SRL", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 400, "start_date": "2019-03-28", "completion_date": "2022-02-14", "has_results": true, "last_update_posted_date": "2026-09-25", "last_synced_at": "2026-10-02T11:23:18.810Z", "location_count": 33, "location_summary": "Phoenix, Arizona • San Diego, California • Tustin, California + 30 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "San Diego", "state": "California" }, { "city": "Tustin", "state": "California" }, { "city": "Palm Harbor", "state": "Florida" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03896581" }, { "nct_id": "NCT00742209", "title": "Prevention Study in Adult Patients Suffering From Migraine Headaches", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Migraine Disorders", "Migraine" ], "interventions": [ { "name": "GSK1838262", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "XenoPort, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 526, "start_date": "2008-08", "completion_date": "2010-06", "has_results": true, "last_update_posted_date": "2013-07-22", "last_synced_at": "2026-10-02T11:23:18.810Z", "location_count": 45, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Anaheim, California + 37 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Anaheim", "state": "California" }, { "city": "Newport Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00742209" }, { "nct_id": "NCT00755820", "title": "Food Exposure Therapy in Anorexia Nervosa", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Anorexia Nervosa" ], "interventions": [ { "name": "Exposure Therapy + D-Cycloserine", "type": "BEHAVIORAL" }, { "name": "Exposure Therapy + Placebo", "type": "BEHAVIORAL" }, { "name": "Supportive Psychotherapy", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "New York State Psychiatric Institute", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 32, "start_date": "2008-01", "completion_date": "2012-01", "has_results": false, "last_update_posted_date": "2012-10-26", "last_synced_at": "2026-10-02T11:23:18.810Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00755820" }, { "nct_id": "NCT06538558", "title": "Study to Assess the Use of Tezampanel for Opioid Withdrawal Syndrome in Treatment-Seeking Patients With Opioid Use Disorder", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Opioid Use Disorder" ], "interventions": [ { "name": "Tezampanel", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Proniras Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 40, "start_date": "2024-10-16", "completion_date": "2027-11-30", "has_results": false, "last_update_posted_date": "2026-09-17", "last_synced_at": "2026-10-02T11:23:18.810Z", "location_count": 1, "location_summary": "Indianapolis, Indiana", "locations": [ { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT06538558" }, { "nct_id": "NCT01405508", "title": "Safety and Tolerability of Intravenous Brivaracetam (Infusion or Bolus) as Adjunctive Antiepileptic Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Epilepsy" ], "interventions": [ { "name": "Brivaracetam tablets", "type": "DRUG" }, { "name": "Brivaracetam bolus", "type": "DRUG" }, { "name": "Brivaracetam infusion", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "UCB Pharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "16 Years to 70 Years" }, "enrollment_count": 105, "start_date": "2011-08", "completion_date": "2012-07", "has_results": true, "last_update_posted_date": "2018-07-11", "last_synced_at": "2026-10-02T11:23:18.810Z", "location_count": 8, "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Lexington, Kentucky + 5 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Lexington", "state": "Kentucky" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01405508" }, { "nct_id": "NCT03984812", "title": "Evaluation of the Safety, Tolerability and Pharmacokinetics (PK) of GSK3732394 First-Time-in-Human (FTIH) Study", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "GSK3732394", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 24, "start_date": "2019-06-17", "completion_date": "2020-03-23", "has_results": true, "last_update_posted_date": "2021-10-25", "last_synced_at": "2026-10-02T11:23:18.810Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03984812" }, { "nct_id": "NCT01963208", "title": "Phase 3 Study of Adjunctive Ganaxolone in Adults With Drug-resistant Partial Onset Seizures and Open-label Extension", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Drug Resistant Partial Onset Seizure" ], "interventions": [ { "name": "ganaxolone", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Marinus Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 405, "start_date": "2013-10", "completion_date": "2016-10", "has_results": true, "last_update_posted_date": "2023-02-14", "last_synced_at": "2026-10-02T11:23:18.810Z", "location_count": 33, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 25 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Sun City", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01963208" } ] }